ArticleFrontiers in public health2024
JN.1: enhanced immune evasion ability propels it to become the predominant strain in China, unlikely to trigger pandemic similar to late 2022.
Article in Frontiers in public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Due to the widespread presence of susceptible populations, the pandemic caused by BA.5 subbranches swiftly disseminated China, impacting the majority of individuals within a span of 1 to 2 months. Subsequently, XBB and its subbranches became the dominant variants in China. Methods: We tracked the immune landscape in the population after the SARS-CoV-2 pandemic in late 2022 in China. Results: Our findings suggested that low levels of neutralizing antibodies against BA.5 subbranches before the pandemic might have contributed to the national outbreak at the end of 2022. The widespread breakthrough infections subsequently increased immunity to BA.5, XBB.1.5/1.9.1, and JN.1, inhibiting a new wave of large-scale infections caused by XBB subbranches in China. Additionally, JN.1 demonstrated enhanced immune evasion capabilities; however, Chinese residents had comparable levels of neutralizing antibodies against JN.1 as those observed for XBB.1.5 among confirmed cases at the end of 2022. Discussion: We anticipate that JN.1 will replace XBB subbranches as the predominant epidemic variant in subsequent transmissions within China. However, it is unlikely to cause a large-scale spread comparable to that witnessed at the end of 2022, with transmission patterns potentially resembling those observed for XBB post-pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.